Last week, patients, physicians, and industry representatives traveled to Washington, DC, to advocate for increased funding for and access to focused ultrasound.
The event was hosted by the Foundation in partnership with the Medical Imaging & Technology Alliance.
OxSonics announced the first patient has been dosed in the final stage of their clinical trial treating colorectal cancer that has spread to the liver.
The trial is evaluating the company’s SonoTran platform, which pumps unmodified oncology drugs at the tumor site to enhance their effectiveness.
This most recent participant was the first to receive chemotherapy drugs in addition to SonoTran.
“Using sound waves to ablate a spot in the brain that controls tremors – that is science fiction. That is so cool.”
‒ John Dutton, Patient
Manage Cookie Consent
We use cookies to optimize our website and our service.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
By using FUSF’s AI agent, you acknowledge and agree that your use is governed by FUSF’s Terms of Use Agreement. If you do not agree to be bound by the Terms of Use Agreement, you may not access or use FUSF’s AI agent.
